Former FDA regulator predicts Cannabis rescheduling this yea Former regulator Howard Sklamberg believes the business consequences from such a move would all be positive.
A longtime attorney at the U.S. Food and Drug Administration who helped found the agency’s Marijuana Working Group in 2014 Howard Sklamberg is now involved in federal cannabis policy on behalf of multistate operator Columbia Care.
Sklamberg recently spoke with Green Market Reportabout the ongoing federal review of cannabis as a Schedule 1 drug – which he believes will result in the Biden administration rescheduling the plant and its derivatives this year or early in 2024.
“Certainly this calendar year,” Sklamberg said, emphasizing he has no “insider” knowledge of any internal timelines set by either the Department of Health and Human Services or the Department of Justice, both of which will play crucial roles in the process.
“The latest will be the first quarter of next year, because you want to get the things settled before you get into the political season,” Sklamberg predicted. “I don’t think they would want this to be one of the things that are floating around a year from now.”
https://420intel.com/articles/2023/08/08/former-fda-regulator-predicts-cannabis-rescheduling-year